Serum lipid parametes | Baseline | 12 weeks | *P value |
---|---|---|---|
LDL-C, mg/dL | |||
Rosuva/Eze 2.5/10 mg | 111 ± 26 | 75 ± 18 | < 0.001 |
Rosuva 5 mg | 112 ± 22 | 98 ± 22 | < 0.001 |
sdLDL-C, mg/dL | |||
Rosuva/Eze 2.5/10 mg | 34 ± 11 | 22 ± 7 | < 0.001 |
Rosuva 5 mg | 34 ± 11 | 28 ± 11 | 0.001 |
MDA-LDL, U/L | |||
Rosuva/Eze 2.5/10 mg | 112 ± 29 | 86 ± 22 | < 0.001 |
Rosuva 5 mg | 117 ± 34 | 100 ± 30 | 0.003 |
HDL-C, mg/dL | |||
Rosuva/Eze 2.5/10 mg | 57 ± 16 | 57 ± 16 | 0.861 |
Rosuva 5 mg | 56 ± 11 | 58 ± 13 | 0.185 |
LDL/HDL ratio | |||
Rosuva/Eze 2.5/10 mg | 2.1 ± 0.8 | 1.4 ± 0.4 | < 0.001 |
Rosuva 5 mg | 2.0 ± 0.5 | 1.8 ± 0.5 | < 0.001 |
TG, mg/dL | |||
Rosuva/Eze 2.5/10 mg | 147 ± 71 | 118 ± 56 | 0.001 |
Rosuva 5 mg | 147 ± 79 | 136 ± 68 | 0.700 |
RLP-C, mg/dL | |||
Rosuva/Eze 2.5/10 mg | 4.9 ± 2.9 | 3.0 ± 1.1 | < 0.001 |
Rosuva 5 mg | 4.7 ± 2.5 | 3.7 ± 1.4 | 0.004 |
Patients achieveing specified LDL-C target | Baseline | 12 weeks | |
Patients achieving LDL-C < 80, n (%) | |||
Rosuva/Eze 2.5/10 mg | 0 (0) | 24 (61.5)† | |
Rosuva 5 mg | 0 (0) | 8 (22.2) | |
Patients achieving LDL-C < 100, n (%) | |||
Rosuva/Eze 2.5/10 mg | 17 (43.6) | 35 (89.7)† | |
Rosuva 5 mg | 11 (30.6) | 21 (58.3) |